Epalrestat is currently the only clinically available aldose reductase(AR) inhibitor . By inhibiting sorbitol accumulation, it ameliorates both subjective symptoms (numbness, pain) and objective neurological dysfunction in diabetic peripheral neuropathy, making it a first-line treatment for diabetic neuropathy.
GMP、DMF
